With the FDA telling Sunesis Pharmaceuticals Inc. it wants additional clinical evidence on the experimental acute myeloid leukemia (AML) drug Qinprezo (vosaroxin) before backing submission of a new drug application (NDA), the company said it will "evaluate and refine" its U.S. plans while pursuing marketing approval for the drug in Europe, where regulators appear receptive to moving ahead with existing data.